BEYOND OZEMPIC: THE NEW TRIPLE AGONIST AND CARDIOVASCULAR RISK

The emergence of novel metabolic therapies has transformed the management of obesity and cardiometabolic diseases. In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, have demonstrated significant benefits in weight reduction and cardiovascular risk modulation. This study aimed to analyze the therapeutic potential of next-generation triple agonists that simultaneously target GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, highlighting their metabolic and cardiovascular implications. An integrative literature review was conducted using PubMed, Scopus, and SciELO databases, covering publications from 2019 to 2025. The findings indicate that triple agonist therapies may produce superior metabolic outcomes compared with traditional GLP-1 receptor agonists, promoting greater weight loss, improved glycemic control, and favorable effects on lipid metabolism and cardiovascular risk markers. Additionally, early clinical evidence suggests potential cardioprotective mechanisms associated with improved metabolic regulation and reduced systemic inflammation. It is concluded that these emerging therapies represent a promising advancement beyond current GLP-1–based treatments, although further long-term clinical trials are required to establish their safety, efficacy, and role in cardiovascular risk reduction.